[go: up one dir, main page]

BR9808263A - Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto. - Google Patents

Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.

Info

Publication number
BR9808263A
BR9808263A BR9808263-9A BR9808263A BR9808263A BR 9808263 A BR9808263 A BR 9808263A BR 9808263 A BR9808263 A BR 9808263A BR 9808263 A BR9808263 A BR 9808263A
Authority
BR
Brazil
Prior art keywords
human
compound
processes
treatment
need
Prior art date
Application number
BR9808263-9A
Other languages
English (en)
Inventor
Cynthia A Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9808263A publication Critical patent/BR9808263A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"PROCESSOS PARA TRATAR CâNCER EM UM HUMANO EM NECESSIDADE DE TRATAMENTO, E, USO DE UM COMPOSTO". Esta invenção fornece um processo para tratar câncer em um indivíduo, em que o câncer é um tumor em que o endotélio é supra-regulado (p.ex., tumores, pulmão, fígado, mama, cérebro, estómago, colon, endométrio, testículos, tiróide, pituitária, bexiga, rins, pâncreas e meninges) pela administração ao indivíduo de uma quantidade eficaz de um composto de fórmula (I) ou fórmula (Ia), como aqui descrito.
BR9808263-9A 1997-03-14 1998-03-09 Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto. BR9808263A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/818,622 US6030975A (en) 1997-03-14 1997-03-14 Carboxylic acid derivatives, their preparation and use in treating cancer
PCT/US1998/004596 WO1998041206A1 (en) 1997-03-14 1998-03-09 Novel carboxylic acid derivatives, their preparation and use in treating cancer

Publications (1)

Publication Number Publication Date
BR9808263A true BR9808263A (pt) 2000-05-16

Family

ID=25225984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808263-9A BR9808263A (pt) 1997-03-14 1998-03-09 Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.

Country Status (19)

Country Link
US (1) US6030975A (pt)
EP (1) EP0969841A1 (pt)
JP (1) JP2001517220A (pt)
KR (1) KR20000076252A (pt)
CN (1) CN1251991A (pt)
AU (2) AU734696B2 (pt)
BG (1) BG103729A (pt)
BR (1) BR9808263A (pt)
CA (1) CA2283732A1 (pt)
HR (1) HRP980126A2 (pt)
HU (1) HUP0002249A3 (pt)
ID (1) ID24283A (pt)
IL (1) IL131666A0 (pt)
NO (1) NO994426L (pt)
NZ (1) NZ337557A (pt)
PL (1) PL335688A1 (pt)
SK (1) SK125299A3 (pt)
WO (1) WO1998041206A1 (pt)
ZA (1) ZA982136B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
BR0017120A (pt) * 2000-02-16 2003-01-14 Yamanouchi Pharma Co Ltd Composição farmacêutica
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20080262006A1 (en) 2007-02-02 2008-10-23 Harbeson Scott L Selective endothelin type-a antagonists
AU2010328230B2 (en) 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
CN102276536B (zh) * 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103709106A (zh) * 2013-12-06 2014-04-09 石家庄博策生物科技有限公司 一种立体选择性制备安立生坦的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072390A1 (en) * 1991-07-01 1993-01-02 Philip D. Stein Endothelin analogues with alpha-amine substitution at residue 20
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
EP0670737A4 (en) * 1992-03-26 1996-05-29 Gensia Inc IN VIVO PEPTIDE THERAPY.
AU678357B2 (en) * 1992-04-22 1997-05-29 Warner-Lambert Company Endothelin antagonists II
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP2847969B2 (ja) * 1993-08-18 1999-01-20 萬有製薬株式会社 エンドセリン拮抗活性を有する複素芳香環縮合シクロペンテン誘導体
HUT74179A (en) * 1993-08-19 1996-11-28 Warner Lambert Co Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
ES2179881T3 (es) * 1994-08-19 2003-02-01 Abbott Lab Antagonistas de endotelina.
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
CA2211646C (en) * 1995-01-27 2008-09-09 Rhone Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
IL116916A (en) * 1995-02-06 2000-09-28 Bristol Myers Squibb Co Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
AU744019B2 (en) 2002-02-14
ID24283A (id) 2000-07-13
HUP0002249A3 (en) 2001-11-28
CA2283732A1 (en) 1998-09-24
EP0969841A1 (en) 2000-01-12
BG103729A (en) 2000-04-28
AU734696B2 (en) 2001-06-21
NO994426L (no) 1999-11-12
CN1251991A (zh) 2000-05-03
KR20000076252A (ko) 2000-12-26
HRP980126A2 (en) 1998-12-31
IL131666A0 (en) 2001-01-28
HUP0002249A2 (hu) 2001-05-28
WO1998041206A1 (en) 1998-09-24
ZA982136B (en) 1999-09-13
SK125299A3 (en) 2001-12-03
NO994426D0 (no) 1999-09-13
US6030975A (en) 2000-02-29
JP2001517220A (ja) 2001-10-02
NZ337557A (en) 2001-08-31
PL335688A1 (en) 2000-05-08

Similar Documents

Publication Publication Date Title
GR3032511T3 (en) Combination with anti-hormonal compounds and binding molecules for the treatment of cancer.
JP2007523862A5 (pt)
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
BR9808263A (pt) Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
EP1458734A4 (en) ISOINDIGO, INDIGO AND INDIRUBIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
DE69519924D1 (de) Gammaglobuline enthaltende immunotherapeutische präparate für die behandlung von krebskrankheiten
BR0215689A (pt) Composição farmacêutica compreendendo arsênico para o tratamento de malignidade
BR9916391A (pt) Compostos de triazineona para o tratamento de doenças causadas por sarcosiste, neopora e toxoplasma
WO2003009809A3 (en) Cancer treatment with gö6976 and its related compounds
WO2002074756A3 (de) Urokinase-inhibitoren
BR9916417A (pt) Compostos triazinaona para tratamento de doenças devidas à sarcosystis, neospora e toxoplasma
MXPA05006722A (es) Metodo para tratamiento de pacientes con exposicion a radiacion.
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.